Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Accounts Payables: 2018-2025

Historic Accounts Payables for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $5.5 million.

  • Arcturus Therapeutics Holdings' Accounts Payables fell 45.80% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 45.80%. This contributed to the annual value of $7.2 million for FY2024, which is 36.28% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Accounts Payables stood at $5.5 million, which was down 48.31% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Accounts Payables registered a high of $19.3 million during Q1 2023, and its lowest value of $5.3 million during Q4 2023.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Accounts Payables value was $10.1 million (recorded in 2024), while the average stood at $10.8 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Accounts Payables surged by 136.36% in 2023 and then slumped by 52.73% in 2024.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Accounts Payables stood at $10.1 million in 2021, then decreased by 25.94% to $7.4 million in 2022, then dropped by 29.13% to $5.3 million in 2023, then surged by 36.28% to $7.2 million in 2024, then tumbled by 45.80% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $10.6 million for Q2 2025, and $6.2 million during Q1 2025.